GLP-1 Receptor Agonists and the Risk of Thyroid Cancer

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

(2019) M. Angelyn Bethel et al.   DIABETES CARE

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial

(2018) Michael A. Nauck et al.   DIABETES CARE

Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study

(2018) Caihua Liang et al.   DIABETES OBESITY & METABOLISM

The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology

(2017) Julien Bezin et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine

(2017) Yuejia Song et al.   Oncology Letters

Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents

(2015) Richard A. Byrd et al.   ENDOCRINOLOGY

A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer

(2012) Carlos Alves et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Effect of exendin (exenatide)—GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model

(2012) Deepti Bulchandani et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Incretin Receptors in Non-Neoplastic and Neoplastic Thyroid C Cells in Rodents and Humans: Relevance for Incretin-Based Diabetes Therapy

(2011) Beatrice Waser et al.   NEUROENDOCRINOLOGY

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

(2010) Lotte Bjerre Knudsen et al.   ENDOCRINOLOGY